Pfizer filed multiple lawsuits in Delaware seeking to block Novo Nordisk’s attempt to acquire obesity biotech Metsera, alleging breach of contract and an anticompetitive plot to eliminate a U.S. competitor. Metsera called Pfizer’s claims “nonsense” and asked the court to deny Pfizer’s request for emergency relief. The legal fight risks delaying or derailing a potential transaction that would reshape the GLP‑1 competitive landscape and draw antitrust scrutiny given Novo’s market position.